Medical Report: Half of US adults could be eligible for a popular weight loss drug
A new report finds half of adults in the United States could be eligible for popular weight loss drugs. KYW medical editor Dr. Brian McDonough has more.
Popular Weight Loss Drugs Could Affect Your Behavior: Scientists Conduct Genetic Investigation
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), widely used medications for managing type 2 diabetes and obesity,
The mechanism behind behavioral side effects of popular weight loss drugs
Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been linked with behavioral side effects.
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
The Health Risks and Benefits of Weight-Loss Drugs
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.In report published in Nature Medicine,
Researchers reveal benefits, risks linked to popular weight-loss drugs
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,
Chip Chick on MSN7h
It Looks Like Scientists Have Uncovered A Natural Alternative To Ozempic
Scientists may have discovered a way to naturally regulate blood sugar levels and sugar cravings that works similarly to ...
Scientists find Ozempic may treat cancer, Alzheimer's and more. Is it hype or truly a "wonder drug?"
Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...
FiercePharma2d
Xeris, stymied by forgetful physicians, partners with ADA to raise awareness of need for glucagon
Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of ...
Websites selling compounded GLP-1 RAs often misinform consumers, research reveals
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
Pharm Exec2d
ADA Partners with Xeris for Glucagon Educational Campaign
The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...
Medical News Today3d
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Immune cells orchestrate glucagon production during fasting
When we think about the immune system, we usually associate it with fighting infections. However, a study published in Science by the Champalimaud Foundation reveals a surprising new role.
HME News2d
ADA, Xeris partner on glucagon campaign
CHICAGO and ARLINGTON, Va. - The American Diabetes Association and a national supporter, Xeris Pharmaceuticals, have formed a multi-year strategic partnership to reinforce the importance of prescribin ...
GEN8d
Mass Migration of Immune Cells Found to Regulate Blood Glucose Levels
Findings suggest targeting neuro-immune pathway could lead to strategies for managing diabetes, obesity or some types of ...
Too Old to Operate2d
GLP1RA Use Increases Solid RGCs and Aborted Procedures in Endoscopy
The following is a summary of “Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist Use ...